-+ 0.00%
-+ 0.00%
-+ 0.00%
According to an announcement from Rundu Co., Ltd., the company's innovative drug, normethylococcal hydrochloride injection, was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. This drug is a class 1 chemical and the world's first novel drug. It is the only beta-agonist type nuclide myocardial perfusion cardiac stress test drug approved in China. It is suitable for nuclide myocardial perfusion imaging to evaluate myocardial ischemia. The agreement is valid from January 1, 2027 to December 31, 2028. The inclusion of medical insurance this time will improve product accessibility, facilitate product marketing, and play a positive role in product sales.
Share
Listen to the news
According to an announcement from Rundu Co., Ltd., the company's innovative drug, normethylococcal hydrochloride injection, was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. This drug is a class 1 chemical and the world's first novel drug. It is the only beta-agonist type nuclide myocardial perfusion cardiac stress test drug approved in China. It is suitable for nuclide myocardial perfusion imaging to evaluate myocardial ischemia. The agreement is valid from January 1, 2027 to December 31, 2028. The inclusion of medical insurance this time will improve product accessibility, facilitate product marketing, and play a positive role in product sales.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending